Paroxetine effects on morphine analgesic tolerance in rats.
analgesic effects
morphine
paroxetine
rats
tolerance
Journal
Scandinavian journal of pain
ISSN: 1877-8879
Titre abrégé: Scand J Pain
Pays: Germany
ID NLM: 101520867
Informations de publication
Date de publication:
27 01 2022
27 01 2022
Historique:
received:
14
01
2021
accepted:
05
07
2021
pubmed:
24
7
2021
medline:
7
4
2022
entrez:
23
7
2021
Statut:
epublish
Résumé
To alleviate different pain intensities, morphine administration has been extensively used. However, prolonged administration of morphine leads to a progressive decline of its analgesic effect which limits their overall utility. Morphine tolerance is considered as a challenging issue for the treatment of both acute and chronic pain. We conducted this study in rats to investigate the effect of paroxetine on morphine tolerance when used preemptively or after morphine tolerance had developed. Male Wistar rats (weight 250-300 g, n=10) were used to evaluate the effects of paroxetine on tolerance to morphine. In order to induce tolerance, daily intraperitoneal injection of morphine (7 mg/kg) was done. After tolerance induction, a group of animals received intraperitoneal injection of 10 mg/kg paroxetine 30 min prior to each morphine dose. In another trial, to investigate the potential of paroxetine to prevent tolerance to morphine, animals were pretreated with 10 mg/kg paroxetine 30 min before morphine administration. In the control groups, 10 mL/kg of saline was injected. The behavioral test (tail-flick test) was done for all groups. Our data showed that paroxetine significantly reversed tolerance to morphine when used after tolerance induction (p<0.001). However, administration of paroxetine before occurrence of tolerance had no effect. We conclude that paroxetine could decrease tolerance to morphine when used after the occurrence of morphine tolerance, while it was not able to prevent morphine tolerance when administered preemptively. IRIB.SBMU.MSP.REC.1394.098.
Identifiants
pubmed: 34298592
pii: sjpain-2021-0009
doi: 10.1515/sjpain-2021-0009
doi:
Substances chimiques
Analgesics
0
Paroxetine
41VRH5220H
Morphine
76I7G6D29C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
186-192Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Merskey, HE. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain 1986;3(Supp):S1–225.
Vos, T, Allen, C, Arora, M, Barber, RM, Bhutta, ZA, Brown, A, et al.. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602. https://doi.org/10.1016/S0140-6736(16)31678-6.
Berry, PH, Chapman, CR, Covington, EC, Dahl, JL, Katz, JA, Miaskowski, C, et al.. Pain: current understanding of assessment, management, and treatments. Natl Pharm Counc Jt Comm Accredit Health Organ VA, USA 2001:b44.
Rosenblum, A, Marsch, LA, Joseph, H, Portenoy, RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 2008;16:405–16. https://doi.org/10.1037/a0013628.
Eisenstein, TK. The role of opioid receptors in immune system function. Front Immunol 2019;10:2904. https://doi.org/10.3389/fimmu.2019.02904.
Bajwa, ZH, Simopoulos, TT, Pal, J, Kraemer, JJ, Chopra, P, Nagda, J, et al.. Low and therapeutic doses of antidepressants are associated with similar response in the context of multimodal treatment of pain. Pain Physician 2009;12:893–900. https://doi.org/10.36076/ppj.2009/12/893.
Mercer S, L, Coop, A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem 2011;11:1157–64. https://doi.org/10.2174/156802611795371288.
Wang, ZJ, Wang, LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci 2006;79:1681–91. https://doi.org/10.1016/j.lfs.2006.05.023.
Salimi, A, Sabetkasaei, M, Raisi, H, Labibi, F, Ameli, H, Khazaei-Poul, Y, et al.. Carbamazepine effects on pain management and serum IL-6, IL-10 evaluation in addicted patients undergoing surgery. Eur J Pharmacol 2017;812:184–8. https://doi.org/10.1016/j.ejphar.2017.07.011.
Bardin, L, Colpaert, FC. Role of spinal 5-HT1A receptors in morphine analgesia and tolerance in rats. Eur J Pain 2004;8:253–61. https://doi.org/10.1016/j.ejpain.2003.09.002.
Pytliak, M, Vargová, V, Mechírová, V, Felšci, M. Serotonin receptors - from molecular biology to clinical applications. Physiol Res 2011;60:15–25. https://doi.org/10.33549/physiolres.931903.
Ozdemir, E. The pathophysiological role of serotonin receptor systems in opioid analgesia and tolerance. Int J Basic Clin Pharmacol 2017;6:217. https://doi.org/10.18203/2319-2003.ijbcp20170312.
Jeong, CY, Choi, JI, Yoon, MH. Roles of serotonin receptor subtypes for the antinociception of 5-HT in the spinal cord of rats. Eur J Pharmacol 2004;502:205–11. https://doi.org/10.1016/j.ejphar.2004.08.048.
Sounvoravong, S, Nakashima, MN, Wada, M, Nakashima, K. Decrease in serotonin concentration in raphe magnus nucleus and attenuation of morphine analgesia in two mice models of neuropathic pain. Eur J Pharmacol 2004;484:217–23. https://doi.org/10.1016/j.ejphar.2003.11.028.
Nayebi, ARM, Charkhpour, M. Role of 5-HT1A and 5-HT2 receptors of dorsal and median raphe nucleus in tolerance to morphine analgesia in rats. Pharmacol Biochem Behav 2006;83:203–7. https://doi.org/10.1016/j.pbb.2006.01.008.
Jolas, T, Nestler, EJ, Aghajanian, GK. Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 1999;95:433–43. https://doi.org/10.1016/S0306-4522(99)00436-4.
Li, JY, Wong, CH, Huang, EYK, Lin, YC, Chen, YL, Tan, PPC, et al.. Modulations of spinal serotonin activity affect the development of morphine tolerance. Anesth Analg 2001;92:1563–8. https://doi.org/10.1097/00000539-200106000-00043.
Arends, RH, Hayashi, TG, Luger, TJ, Shen, DD. Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats. J Pharmacol Exp Therapeut 1998;286:585–92. PMID: 9694907.
Singh, VP, Jain, NK, Kulkarni, SK. Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways. Methods Find Exp Clin Pharmacol 2003;25:273–80. https://doi.org/10.1358/mf.2003.25.4.769675.
Zarei, M, Sabetkasaei, M, Moini Zanjani, T. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J 2014;18:94. https://doi.org/10.6091/ibj.1282.2013.
Nevels, RM, Gontkovsky, ST, Williams, BE. Paroxetine—the antidepressant from hell? Probably not, but caution required. Psychopharmacol Bull 2016;46:77–104. PMID: 27738376.
Nencetti, S, Demontis, GC, Mazzoni, MR, Betti, L, Banti, I, Rossello, A, et al.. 3-[(Aryl)(4-Fluorobenzyloxy)Methyl]Piperidine derivatives: high-affinity ligands for the serotonin transporter. J Pharm Pharmacol 2010;59:1439–45. https://doi.org/10.1211/jpp.59.10.0016.
Iyengar, S, Webster, AA, Hemrick-Luecke, SK, Xu, JY, Simmons, RMA. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Therapeut 2004;311:576–84. https://doi.org/10.1124/jpet.104.070656.
Sindrup, SH, Otto, M, Finnerup, NB, Jensen, TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399–409. https://doi.org/10.1111/j.1742-7843.2005.pto_96696601.x.
Zarei, M, Sabetkasaei, M, Moini-Zanjani, T. Effect of paroxetine on the neuropathic pain: a molecular study. Iran Biomed J 2020;24:306. https://doi.org/10.29252/ibj.24.5.301.
Gutiérrez, M, Ortega-Álvaro, A, Gibert-Rahola, J, Micó, JA. Interactions of acute morphine with chronic imipramine and fluvoxamine treatment on the antinociceptive effect in arthritic rats. Neurosci Lett 2003;352:37–40. https://doi.org/10.1016/j.neulet.2003.08.020.
Rosland, JH, Hunskaar, S, Hole, K. Modification of the antinociceptive effect of morphine by acute and chronic administration of clomipramine in mice. Pain 1988;33:349–55. https://doi.org/10.1016/0304-3959(88)90295-3.
Godefroy, F, Butler, SH, Weil-Fugazza, J, Besson, JM. Do acute or chronic tricyclic antidepressants modify morphine antinociception in arthritic rats? Pain 1986;25:233–44. https://doi.org/10.1016/0304-3959(86)90099-0.
Juś, A, Bujalska, M, Makulska-Nowak, HE. Modification of fentanyl analgesia by antidepressants. Pharmacology 2010;85:48–53. https://doi.org/10.1159/000268105.
Ozdemir, E, Gursoy, S, Bagcivan, I. The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. J Physiol Sci 2012;62:317–23. https://doi.org/10.1007/s12576-012-0207-x.
Ozdemir, E, Gursoy, S, Bagcivan, I, Durmus, N, Altun, A. Zimelidine attenuates the development of tolerance to morphine-induced antinociception. Indian J Pharmacol 2012;44:215–8. https://doi.org/10.4103/0253-7613.93851.
Sikka, P, Kaushik, S, Kumar, G, Kapoor, S, Bindra, VK, Saxena, KK. Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazepine) and their interaction with morphine and naloxone in mice. J Pharm Bioallied Sci 2011;3:412–6. https://doi.org/10.4103/0975-7406.84454.
Nayebi, AM, Rezazadeh, H, Parsa, Y. Effect of fluoxetine on tolerance to the analgesic effect of morphine in mice with skin cancer. Pharmacol Rep 2009;61:453–8. https://doi.org/10.1016/S1734-1140(09)70086-6.
Nayebi, AM, Rezazadeh, H, Nourafkan, M. Buspirone attenuates tolerance to analgesic effect of morphine in mice with skin cancer. Pak J Pharm Sci 2010;23:201–6. PMID: 20363700.
Hamdy, MM, Elbadr, MM, Barakat, A. Bupropion attenuates morphine tolerance and dependence: possible role of glutamate, norepinephrine, inflammation, and oxidative stress. Pharmacol Rep 2018;70:955–62. https://doi.org/10.1016/j.pharep.2018.04.003.
Pasternak, GW, Pan, YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 2013;65:1257–317. https://doi.org/10.1124/pr.112.007138.
Abdel-Zaher, AO, Mostafa, MG, Farghaly, HSM, Hamdy, MM, Abdel-Hady, RH. Role of oxidative stress and inducible nitric oxide synthase in morphine-induced tolerance and dependence in mice. Effect of alpha-lipoic acid. Behav Brain Res 2013;247:17–26. https://doi.org/10.1016/j.bbr.2013.02.034.
Toda, N, Kishioka, S, Hatano, Y, Toda, H. Modulation of opioid actions by nitric oxide signaling. Anesthesiology 2009;110:166–81. https://doi.org/10.1097/ALN.0b013e31819146a9.
Xu, J, Faskowitz, AJ, Rossi, GC, Xu, M, Lu, Z, Pan, YX, et al.. Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs. Proc Natl Acad Sci U S A 2015;112:279–84. https://doi.org/10.1073/pnas.1419183112.
Vilpoux, C, Carpentier, C, Leroux-Nicollet, I, Naudon, L, Costentin, J. Differential effects of chronic antidepressant treatments on μ- and δ-opioid receptors in rat brain. Eur J Pharmacol 2002;443:85–93. https://doi.org/10.1016/S0014-2999(02)01585-6.
Maura, G, Marcoli, M, Pepicelli, O, Rosu, C, Viola, C, Raiteri, M. Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors. Br J Pharmacol 2000;130:1853–8. https://doi.org/10.1038/sj.bjp.0703510.
Kosten, T, Oliveto, A, Feingold, A, Poling, J, Sevarino, K, McCance-Katz, E, et al.. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003;70:315–25. https://doi.org/10.1016/S0376-8716(03)00032-2.
Liu, KS, Chen, SJ, Chen, YW, Sung, KC, Wang, JJ. A dose-response study on the efficacy of tricyclic antidepressants on reducing morphine-withdrawal symptoms. Acta Anaesthesiol Taiwanica 2013;51:18–21. https://doi.org/10.1016/j.aat.2013.03.002.